176 related articles for article (PubMed ID: 12782714)
1. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.
Kari L; Loboda A; Nebozhyn M; Rook AH; Vonderheid EC; Nichols C; Virok D; Chang C; Horng WH; Johnston J; Wysocka M; Showe MK; Showe LC
J Exp Med; 2003 Jun; 197(11):1477-88. PubMed ID: 12782714
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
3. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.
Laharanne E; Oumouhou N; Bonnet F; Carlotti M; Gentil C; Chevret E; Jouary T; Longy M; Vergier B; Beylot-Barry M; Merlio JP
J Invest Dermatol; 2010 Jun; 130(6):1707-18. PubMed ID: 20130593
[TBL] [Abstract][Full Text] [Related]
5. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
6. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
[TBL] [Abstract][Full Text] [Related]
7. Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.
Fujii K; Karpova MB; Asagoe K; Georgiev O; Dummer R; Urosevic-Maiwald M
Leukemia; 2015 Oct; 29(10):2024-32. PubMed ID: 25915825
[TBL] [Abstract][Full Text] [Related]
8. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
10. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
11. cDNA microarrays and cutaneous oncology.
Wood GS
Arch Dermatol; 2005 May; 141(5):632. PubMed ID: 15897390
[No Abstract] [Full Text] [Related]
12. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
[TBL] [Abstract][Full Text] [Related]
13. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of T-plastin in Sezary cells.
Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
[TBL] [Abstract][Full Text] [Related]
15. Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations.
Capriotti E; Vonderheid EC; Thoburn CJ; Bright EC; Hess AD
J Invest Dermatol; 2007 Dec; 127(12):2882-92. PubMed ID: 17597825
[TBL] [Abstract][Full Text] [Related]
16. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
18. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis.
Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L
J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102
[TBL] [Abstract][Full Text] [Related]
19. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.
Slater DN
Br J Dermatol; 2005 Nov; 153(5):874-80. PubMed ID: 16225594
[TBL] [Abstract][Full Text] [Related]
20. Functional copy number changes in Sézary syndrome: toward an integrated molecular cytogenetic map III.
Mao X; McElwaine S
Cancer Genet Cytogenet; 2008 Sep; 185(2):86-94. PubMed ID: 18722877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
